Terlikowski S, Sulkowski S, Nowak H F
Department of Gynaecology and Septic Obstetrics, Medical School of Białystok, Poland.
Eur Cytokine Netw. 1997 Sep;8(3):259-63.
We examined the antitumor effects of human recombinant tumor necrosis factor alpha (rhTNF-alpha) and its muteins with the N-terminal amino acid sequence altered by point mutations against transplantable Morris hepatoma 5123 in rats. In vivo studies showed antiproliferative activity of the drugs in the dose range tested. For in vivo studies rhTNF-alpha and muteins were administered intratumorly (i.t.). The preparations were given at a dose of 10 microg/rat, once daily for eight days. Although the therapy was significantly effective in inhibiting tumor growth, complete growth inhibition could not be achieved. Nevertheless, there was a significant increase in survival time of tumor-bearing rats.
我们研究了人重组肿瘤坏死因子α（rhTNF-α）及其N端氨基酸序列经点突变改变的突变体对大鼠可移植性莫里斯肝癌5123的抗肿瘤作用。体内研究表明，在所测试的剂量范围内，这些药物具有抗增殖活性。在体内研究中，rhTNF-α和突变体通过瘤内注射（i.t.）给药。制剂以10μg/大鼠的剂量给药，每天一次，共八天。虽然该疗法在抑制肿瘤生长方面显著有效，但无法实现完全生长抑制。然而，荷瘤大鼠的存活时间有显著延长。
